Insigneo Advisory Services’s BeOne Medicines Ltd ONC Stock Holding History

Insigneo Advisory Services’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$288K	Buy	+1,010	New	+$298K	0.01%	652

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Insigneo Advisory Services's ONC Position: Q2 2026 in Review

Insigneo Advisory Services opened a new position in BeOne Medicines Ltd (ONC) in Q2 2026: 1,010 shares worth $288K. The stake represents 0.01% of the portfolio and ranks #652 among its holdings.

282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Insigneo Advisory Services held 1,010 shares of BeOne Medicines Ltd worth $288K as of Q2 2026.
BeOne Medicines Ltd was a new Insigneo Advisory Services position in Q2 2026.
BeOne Medicines Ltd made up 0.01% of Insigneo Advisory Services's portfolio in Q2 2026, its #652 holding.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Insigneo Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.